Business Context and Reporting Period
Company: eXegenics Inc. (Note: Metadata listed "OPKO HEALTH, INC." but the filing text identifies the registrant as eXegenics Inc.)
Period: Fiscal year ended December 31, 2003
Status: The Company is in a wind-down phase of its drug discovery operations, initiated in late 2002. On December 5, 2003, the "Prior Board" was removed via a proxy consent solicitation and replaced by a "New Board" focused on resolving liabilities and redeploying residual assets. The Company has terminated all research programs and scientific staff, leaving David E. Riggs as the sole employee serving as President, CEO, and CFO.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Revenue | $13,000 | $562,000 |
| Net Loss | $(5,793,000) | $(10,358,000) |
| Loss Per Share (Basic/Diluted) | $(0.38) | $(0.67) |
| Cash and Cash Equivalents | $10,132,000 | $6,138,000 |
| Restricted Cash | $600,000 | $600,000 |
| Total Assets | $11,342,000 | $17,515,000 |
| Working Capital | $10,296,000 | $15,924,000 |
| Stockholders' Equity | $10,304,000 | $16,074,000 |
Debt: Capital lease obligations were terminated in December 2003. No long-term debt is reported on the balance sheet as of December 31, 2003.
Material Changes vs. Prior Period
- Revenue Collapse: Revenue decreased 98% to $13,000 due to the termination of all drug discovery research and related agreements (including the Bristol-Myers Squibb agreement).
- Expense Reduction:
- R&D Expenses: Dropped 96% to $154,000 as research programs were shut down.
- G&A Expenses: Decreased 38% to $2.94 million, driven by reduced headcount and patent costs.
- Merger and M&A Costs: The Company incurred $2.23 million in expenses related to merger, tender offers, and consent solicitations in 2003, compared to $2.01 million in 2002. This includes legal fees, financial advisor fees, and termination fees related to failed deals with IDDS and AVI Biopharma.
- Net Loss Improvement: Net loss decreased by 44% to $5.79 million, primarily due to the cessation of R&D activities.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management anticipates wind-down operations will be substantially completed by the end of the first half of 2004. Estimated cash usage is $1.2–1.5 million to satisfy prior commitments, followed by a forecast of $100,000–$125,000 per month thereafter, assuming no new business operations.
- Liquidity: The Company holds approximately $10.7 million in cash and equivalents. Future capital needs are uncertain; additional financing may be required if a new business strategy is implemented.
- NASDAQ Listing Risk: The Company failed to meet the $1.00 minimum bid price requirement. NASDAQ granted an extension until July 25, 2004, to regain compliance. Failure to meet this standard will result in delisting to the OTC Bulletin Board.
- Legal Proceedings:
- Weiss Litigation: A class action lawsuit alleges mismanagement and breach of fiduciary duties by the Prior Board. The Company is vigorously defending against claims to restore monies allegedly wasted on aborted mergers.
- Landlord Dispute: A dispute with the landlord of the former Dallas facility regarding approximately $173,000 in claims was settled in March 2004 for a $33,000 payment.
- Auditor Change: Ernst & Young LLP resigned as independent auditor in September 2003. BDO Seidman, LLP was engaged in November 2003. No disagreements were reported regarding accounting principles.
Investor Verification Checklist
- Cash Burn Rate: Verify the accuracy of the $100k–$125k monthly burn rate forecast and the sufficiency of the $10.7 million cash balance to sustain operations through the wind-down and potential new strategy.
- NASDAQ Compliance: Monitor stock price performance to ensure the $1.00 minimum bid price is met for 10 consecutive trading days before the July 25, 2004 deadline to avoid delisting.
- Legal Exposure: Assess the potential financial impact of the ongoing Weiss Litigation, specifically regarding the recovery of funds from the Prior Board for failed merger transactions.
- Related Party Transactions: Review the $300,000 promissory note issued to former CEO Dr. Ronald L. Goode, noting the discrepancy between the authorized interest rate (6%) and the actual rate (4.71%), and the limitation of liability clause discovered post-issuance.
- Asset Realization: Confirm the valuation and potential for monetization of remaining intellectual property (QCT, OASIS) and the $10 million government agency debt security.